Skip to main content
Smart Investors Daily
BG

NASDAQ · BGMS

Bio Green Med Solution, Inc.

Healthcare · Medical - Pharmaceuticals

$0.87

Up+$0.03 (+3.18%)

Updated Sep 12, 2026, 11:06 AM

SID Score

3.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
2.95M
P/E ratio
-0.21
Dividend yield
0.00%
52-week range
$0.57 – $2.80
Volume
17.5K
Avg. volume
504.43K

Price performance

BGMS price history

1M range · 20 trading sessions · Daily adjusted prices

BGMS closed at $0.87 after 20 trading sessions, down 4.70% for the selected period.

Last close
$0.87
Period change
-4.70%
Period low
$0.83
Period high
$0.92
Daily close
View OHLC price history
BGMS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$0.852$0.873$0.8451$0.87217.5K
Sep 10, 2026$0.8704$0.8704$0.8451$0.84514.97K
Sep 9, 2026$0.8628$0.883$0.8401$0.85518.42K
Sep 8, 2026$0.88$0.88$0.8559$0.8738.22K
Sep 4, 2026$0.903$0.9035$0.8712$0.903528.81K
Sep 3, 2026$0.8743$0.93$0.8701$0.921619.44K
Sep 2, 2026$0.8499$0.8499$0.83$0.832618.15K
Sep 1, 2026$0.86$0.8707$0.85$0.8520.36K
Aug 31, 2026$0.88$0.892$0.86$0.8657.61K
Aug 28, 2026$0.8904$0.9042$0.86$0.8622.58K
Aug 27, 2026$0.8739$0.9132$0.8739$0.890612.8K
Aug 26, 2026$0.853$0.899$0.851$0.887522.68K
Aug 25, 2026$0.903$0.903$0.877$0.877125.44K
Aug 24, 2026$0.8755$0.8828$0.8655$0.87055.69K
Aug 21, 2026$0.86$0.90$0.86$0.865116.66K
Aug 20, 2026$0.9186$0.922$0.8701$0.875310.08K
Aug 19, 2026$0.91$0.9344$0.8713$0.905312.6K
Aug 18, 2026$0.881$0.9492$0.8704$0.91237.64K
Aug 17, 2026$0.9202$0.93$0.893$0.90919.79K
Aug 14, 2026$0.913$0.95$0.8913$0.9154.69K

Latest BGMS news

The latest Smart Investors Daily articles mentioning BGMS.

BGMS research

Overview

Company profile and research snapshot.

Company profile

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

Generated Sep 12, 2026, 11:01 AM

Why Is BGMS Up Today?

Bio Green Med Solution, Inc. (BGMS) gained 3.18% ($0.03) today, though the modest uptick appears disconnected from direct company news. The stock's movement may reflect broader market sentiment or investor positioning ahead of potential corporate developments, as the biomedical sector continues to monitor regulatory and financing activities.

    Bottom line: BGMS's 3.18% gain today appears to be driven more by broader sector sentiment than company-specific news, making it important for investors to distinguish between momentum and fundamental value. Watch for official company announcements regarding financing, partnerships, or clinical developments that could justify sustained price movement and provide clarity on the investment thesis.

    Yahoo · Sep 10, 2026

    Firstborn Top Capital, a Licensed Private Financing Company in Malaysia, to Become Publicly Traded Via Business Combination with ARC Group Acquisition I Corp

    ~ Transaction values Firstborn Top Capital at pro forma enterprise value of approximately $1,091.2 million ~~ Firstborn Top Capital is a licensed private financing company committed to providing responsible, transparent and accessible financial solutions to individuals and businesses across Malaysia ~~ Executive Director, Ow Ruey Shen, will continue to lead Firstborn Top Capital ~~ Transaction provides Firstborn Top Capital the capital to accelerate growth throughout Malaysia, then Southeast Asi

    Benzinga · Jul 27, 2026

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.